Cesca Therapeutics Company Profile (NASDAQ:KOOL)

About Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics logoCesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KOOL
  • CUSIP: N/A
  • Web: www.cescatherapeutics.com
Capitalization:
  • Market Cap: $34.66 million
  • Outstanding Shares: 9,903,000
Average Prices:
  • 50 Day Moving Avg: $3.34
  • 200 Day Moving Avg: $3.22
  • 52 Week Range: $2.41 - $4.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $14 million
  • Price / Sales: 2.48
  • Book Value: $3.21 per share
  • Price / Book: 1.09
Profitability:
  • EBIDTA: ($6,730,000.00)
  • Net Margins: -225.90%
  • Return on Equity: -33.56%
  • Return on Assets: -23.23%
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 2.25%
  • Quick Ratio: 1.50%
Misc:
  • Average Volume: 91,508 shs.
  • Beta: -0.72
  • Short Ratio: 1.13
 

Frequently Asked Questions for Cesca Therapeutics (NASDAQ:KOOL)

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc. (NASDAQ:KOOL) posted its quarterly earnings data on Tuesday, February, 16th. The company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.05. The business earned $3.29 million during the quarter, compared to analysts' expectations of $4.32 million. Cesca Therapeutics had a negative return on equity of 33.56% and a negative net margin of 225.90%. View Cesca Therapeutics' Earnings History.

When will Cesca Therapeutics make its next earnings announcement?

Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 16th 2017. View Earnings Estimates for Cesca Therapeutics.

Who are some of Cesca Therapeutics' key competitors?

Who are Cesca Therapeutics' key executives?

Cesca Therapeutics' management team includes the folowing people:

  • Xiaochun Xu, Chairman of the Board, Interim Chief Executive Officer
  • Jeff Cauble, Principal Financial Officer, Principal Accounting Officer
  • Venkatesh Ponemone, Executive Director of India Operations, Director of Clinical and Scientific Affairs
  • Vivian Liu, Chief Operating Officer
  • Kimberly Ellner, Vice President of Manufacturing and Global Supply Chain
  • Russell M. Medford M.D., Ph.D., Director
  • Joseph Thomis, Director
  • James Xu, Director
  • Mahendra S. Rao Ph.D., Independent Director
  • Denis Michael Rhein, Independent Director

Who owns Cesca Therapeutics stock?

Cesca Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.62%). Company insiders that own Cesca Therapeutics stock include (Hong Kong) Ltd Boyalife and Kenneth Harris. View Institutional Ownership Trends for Cesca Therapeutics.

Who bought Cesca Therapeutics stock? Who is buying Cesca Therapeutics stock?

Cesca Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Cesca Therapeutics.

How do I buy Cesca Therapeutics stock?

Shares of Cesca Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cesca Therapeutics' stock price today?

One share of Cesca Therapeutics stock can currently be purchased for approximately $3.50.


MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Maxim GroupReiterated RatingHoldLowView Rating Details
9/21/2015HC WainwrightUpgradeNeutral -> Buy$2.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)
Earnings by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Earnings History by Quarter for Cesca Therapeutics (NASDAQ KOOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017N/AView Earnings Details
2/13/2017Q2 2017($0.35)$4.01 millionViewN/AView Earnings Details
11/17/2016Q1 2017($0.34)$3.77 millionViewN/AView Earnings Details
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details
9/17/2015Q415($0.11)($0.06)$4.08 million$3.70 millionViewListenView Earnings Details
6/23/2015Q315($0.08)($0.12)$4.69 million$4.04 millionViewListenView Earnings Details
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details
5/15/2014Q3 2014($0.05)($0.07)$4.04 millionViewN/AView Earnings Details
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details
11/14/2013Q1($0.14)ViewListenView Earnings Details
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
Current Year EPS Consensus Estimate: $-4.5200 EPS
Next Year EPS Consensus Estimate: $-1.1800 EPS

Dividends

Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cesca Therapeutics (NASDAQ:KOOL)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 2.53%
Insider Trades by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Institutional Ownership by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Insider Trades by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/26/2016(Hong Kong) Ltd BoyalifeMajor ShareholderBuy6,102,942$2.52$15,379,413.84View SEC Filing  
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.80View SEC Filing  
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.80View SEC Filing  
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.00View SEC Filing  
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.00View SEC Filing  
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.00View SEC Filing  
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.20View SEC Filing  
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cesca Therapeutics (NASDAQ:KOOL)
Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
Source:
DateHeadline
finance.yahoo.com logoCesca Therapeutics Announces Fiscal Year 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - September 20 at 12:14 AM
americanbankingnews.com logoCesca Therapeutics Inc. (KOOL) Announces Quarterly Earnings Results
www.americanbankingnews.com - September 19 at 8:38 PM
nasdaq.com logoCesca Therapeutics to Announce Fiscal Fourth Quarter and Full Year 2017 Financial Results and Host
www.nasdaq.com - September 13 at 3:48 AM
finance.yahoo.com logoCesca Therapeutics to Announce Fiscal Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on September 19, 2017
finance.yahoo.com - September 13 at 3:47 AM
americanbankingnews.com logoCesca Therapeutics Inc. (KOOL) to Release Earnings on Monday
www.americanbankingnews.com - September 11 at 1:28 AM
finance.yahoo.com logoCESCA Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 3:41 PM
finance.yahoo.com logoCesca Therapeutics to Participate in the CAR-TCR Summit 2017
finance.yahoo.com - September 1 at 2:00 AM
finance.yahoo.com logoDistribution deal could help Rancho Cordova's Cesca expand into growing Asian markets
finance.yahoo.com - August 29 at 3:29 PM
finance.yahoo.com logoCesca Therapeutics Announces International Distribution Agreement With Boyalife WSN Ltd.
finance.yahoo.com - August 25 at 7:46 AM
americanbankingnews.com logoFinancial Analysis: Cesca Therapeutics (KOOL) versus Onconova Therapeutics (ONTX)
www.americanbankingnews.com - August 18 at 6:22 AM
americanbankingnews.com logo Cesca Therapeutics Inc. (KOOL) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 31 at 9:42 AM
americanbankingnews.com logoCesca Therapeutics (KOOL) and Syros Pharmaceuticals (SYRS) Critical Contrast
www.americanbankingnews.com - July 30 at 12:21 PM
bizjournals.com logoCesca stock jumps after company receives cellular processing patent
www.bizjournals.com - July 29 at 1:27 AM
finance.yahoo.com logoCesca Therapeutics Announces Issuance of New Cellular Processing Patent Poised to Revolutionize CAR-T Cell Manufacturing
finance.yahoo.com - July 29 at 1:27 AM
finance.yahoo.com logoBiotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent
finance.yahoo.com - July 29 at 1:27 AM
americanbankingnews.com logoSyndax Pharmaceuticals (SNDX) versus Cesca Therapeutics (KOOL) Head to Head Comparison
www.americanbankingnews.com - July 17 at 6:24 PM
americanbankingnews.com logoCesca Therapeutics (NASDAQ:KOOL) and Transition Therapeutics (TTHI) Head to Head Contrast
www.americanbankingnews.com - July 16 at 10:34 AM
seekingalpha.com logoCesca buys SynGen assets in cash and stock deal
seekingalpha.com - July 13 at 6:13 AM
finance.yahoo.com logoFeatured Company News - Cesca Therapeutics Acquires Cell Processing Systems from SynGen through its Device Business, ThermoGenesis
finance.yahoo.com - July 13 at 6:13 AM
nasdaq.com logoCesca Therapeutics Buys SynGen's Operating Assets; Stock Up
www.nasdaq.com - July 11 at 4:41 AM
finance.yahoo.com logoCesca Therapeutics Acquires the Cell Processing Systems of SynGen Under Asset Acquisition Agreement
finance.yahoo.com - July 10 at 11:37 PM
finance.yahoo.com logoCesca Therapeutics shares jump 11% premarket after SynGen deal
finance.yahoo.com - July 10 at 11:37 PM
finance.yahoo.com logoRancho Cordova's Cesca Therapeutics acquiring Sacramento-based SynGen
finance.yahoo.com - July 10 at 11:37 PM
marketwatch.com logoCesca Therapeutics Set to Join Russell Microcap(R) Index
www.marketwatch.com - June 25 at 6:57 PM
finance.yahoo.com logoCesca Therapeutics Set to Join Russell Microcap® Index
finance.yahoo.com - June 23 at 6:37 PM
finance.yahoo.com logoCesca Therapeutics to Present at the 2017 Marcum MicroCap Conference
finance.yahoo.com - June 12 at 3:22 PM
finance.yahoo.com logoCesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 11:15 AM
finance.yahoo.com logoCesca Therapeutics to Present at the Inaugural Cell and Gene Exchange 2017
finance.yahoo.com - May 18 at 9:01 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 12 at 1:38 PM
reuters.com logoBRIEF-Cesca Therapeutics Q3 loss per share $0.21
www.reuters.com - May 11 at 11:41 PM
seekingalpha.com logoCesca Therapeutics (KOOL) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 11:41 PM
finance.yahoo.com logoInvestor Network: Cesca Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 6:40 PM
finance.yahoo.com logoCesca Therapeutics Announces Fiscal Third Quarter and Nine Month 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - May 11 at 6:40 PM
finance.yahoo.com logoCesca Therapeutics to Announce Fiscal Third Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - May 4 at 6:20 PM
americanbankingnews.com logoCesca Therapeutics (KOOL) Earning Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:00 PM
finance.yahoo.com logoCesca to Exhibit at the 25th International Society for Cellular Therapy (ISCT) Annual Meeting
finance.yahoo.com - May 2 at 4:36 PM
americanbankingnews.com logoCesca Therapeutics (KOOL) Receives Daily Coverage Optimism Score of -0.25
www.americanbankingnews.com - April 23 at 9:05 AM
americanbankingnews.com logoCesca Therapeutics (KOOL) Receives News Sentiment Score of 0.05
www.americanbankingnews.com - April 20 at 11:49 PM
finance.yahoo.com logoCESCA Therapeutics to Present at the 2017 International ... - Yahoo Finance
finance.yahoo.com - April 11 at 10:58 PM
feeds.benzinga.com logoCESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair
feeds.benzinga.com - April 11 at 8:21 AM
americanbankingnews.com logoZacks: Brokerages Expect Cesca Therapeutics Inc (KOOL) Will Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 9 at 8:14 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Short Interest Update
www.americanbankingnews.com - April 8 at 11:08 AM
finance.yahoo.com logoCesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International Precision Medicine Summit
finance.yahoo.com - April 7 at 6:12 PM
finance.yahoo.com logoCesca Therapeutics Announces Senior Management Promotions
finance.yahoo.com - April 4 at 6:31 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Given Hold Rating at Maxim Group
www.americanbankingnews.com - March 21 at 3:40 PM
streetinsider.com logoCesca Therapeutics (KOOL) Announces CLI Feasibility Study Published in Stem Cells International - StreetInsider.com
www.streetinsider.com - March 21 at 12:07 PM
us.rd.yahoo.com logoCesca CLI Feasibility Study Published in Peer-Reviewed Journal
us.rd.yahoo.com - March 20 at 10:42 AM
bizjournals.com logoLocal medical technology company reports positive results from clinical trial
www.bizjournals.com - March 16 at 6:59 PM
finance.yahoo.com logoBlog Coverage Cesca Therapeutics Announces Encouraging Results from a Study of its Treatment of Chronic Non-healing Ulcers
finance.yahoo.com - March 16 at 6:59 PM
finance.yahoo.com logoWednesday's Biggest Biopharma Movers - Yahoo Finance
finance.yahoo.com - March 16 at 4:30 AM

Social

Chart

Cesca Therapeutics (KOOL) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff